SEC Form 4 · accession 0000899243-18-002742
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jung Choi
Officer — See Remarks
Period of report
Jan 31, 2018
Accepted (ET)
Feb 2, 2018 · 8:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 31, 2018 | M | 2,000 | — | A | 138,092 | D | |
| Common StockF2 | Jan 31, 2018 | F | 692 | $57.90 | D | 137,400 | D | |
| Common StockF1 | Feb 1, 2018 | M | 4,063 | — | A | 141,463 | D | |
| Common StockF3 | Feb 1, 2018 | F | 1,405 | $59.60 | D | 140,058 | D | |
| Common Stock | holding | — | — | — | 25,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F4 | — | Jan 31, 2018 | M | 2,000 | D | — | — | Common Stock | 2,000 | 9,000 | D |
| Restricted Stock UnitsF1,F5 | — | Feb 1, 2018 | M | 4,063 | D | — | — | Common Stock | 4,063 | 24,375 | D |
| Stock Option (Right to Buy)F6 | $59.60 | Feb 1, 2018 | A | 35,000 | A | — | Jan 31, 2028 | Common Stock | 35,000 | 35,000 | D |
| Restricted Stock UnitsF1,F7 | — | Feb 1, 2018 | A | 23,000 | A | — | — | Common Stock | 23,000 | 23,000 | D |
Explanation of responses
- F1Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
- F2Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,000 shares of Common Stock underlying the Reporting Person's RSUs.
- F3Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,063 shares of Common Stock underlying the Reporting Person's RSUs.
- F4On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 31, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- F5On January 17, 2017, the Reporting Person was granted 32,500 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- F6The shares underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- F7The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Remarks
Chief Business and Strategy Officer